DF-004

DF-004 is a small molecule drug candidate currently in the candidate selection (preclinical) stage for the treatment of colitis. Developed by Drug Farm, the asset was identified through the company's Medusa platform, a genome-wide screening technology that uses insertional mutagenesis to identify novel disease targets. While the specific molecular target of DF-004 has not been officially disclosed, Drug Farm specializes in the discovery of first-in-class therapies, particularly those modulating the ALPK1 (Alpha-protein kinase 1) pathway. The program is part of a pipeline that leverages genetic insights from both human and animal models to address inflammatory and metabolic diseases.